Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer [Yahoo! Finance]
Acrivon Therapeutics, Inc. (ACRV)
Company Research
Source: Yahoo! Finance
74%, clinical benefit 65%), compared with a 22% response rate in non-serous tumors; the biomarker-positive intent-to-treat group had a 39% ORR and 81% DCR. The study uses Acrivon's OncoSignature protein-based biomarker to prospectively select patients: biomarker-positive patients received ACR-368 monotherapy while biomarker-negative patients received ACR-368 plus ultra-low-dose gemcitabine, with a lower ORR (26%) in the biomarker-negative group suggesting predictive value. The trial is expanding with a biopsy-independent serous cohort (Arm 3) to enroll up to 90 serous patients (=2 prior lines), opening at 20 European sites with expected enrollment start in early Q2 and a target to complete enrollment by end Q3; Arm 3 allows prior ADC therapy and Acrivon remains in active dialogue with the FDA. Interested in Acrivon Therapeutics, Inc.? Here are five stocks we like better. Acrivon Therapeutics (NASDAQ:ACRV) hosted a webcast featuring a key opinion leader (KOL) panel focused on t
Show less
Read more
Impact Snapshot
Event Time:
ACRV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACRV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACRV alerts
High impacting Acrivon Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ACRV
News
- Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]Yahoo! Finance
- Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care ConferenceGlobeNewswire
- Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) CongressGlobeNewswire
- Acrivon Therapeutics (NASDAQ:ACRV) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ACRV&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified LaboratoryGlobeNewswire
ACRV
Earnings
- 5/14/25 - Beat
ACRV
Sec Filings
- 2/27/26 - Form 8-K
- 2/24/26 - Form 4
- 2/18/26 - Form 4
- ACRV's page on the SEC website